Secretin Peptide: ChiRhoStim, Pancreatic and Gastrinoma Diagnostic Use
Secretin peptide guide to ChiRhoStim human secretin: secretin-receptor mechanism, FDA pancreatic and gastrinoma diagnostic uses, reference dosing and safety.
Secretin is one of the oldest known hormones in physiology, and it has a very different profile from the research-market peptides sold for performance or longevity. It is a 27-amino-acid gastrointestinal peptide hormone, and its only US-approved product, ChiRhoStim (human secretin) from ChiRhoClin, is a prescription diagnostic agent given intravenously by clinicians. It is not a self-administered wellness peptide, and there is no labeled therapeutic use.
That distinction matters. Secretin appears in peptide discussions because it is a "natural hormone," but the approved evidence base is about provoking a measurable secretory response during a clinical test, not about treating a disease. Understanding secretin means understanding what a diagnostic stimulant does and, just as importantly, what its failed therapeutic programs taught us.
This guide is educational and not medical advice. Secretin in its approved form is a prescription diagnostic medicine administered in supervised clinical settings. It should never be treated as an at-home protocol.
For broader context, compare this guide with octreotide, which is used in some of the same gastroenteropancreatic tumor settings, teduglutide and linaclotide as other gut-acting peptides, what peptides are, and the peptide half-life guide.
Secretin At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A 27-amino-acid gut peptide hormone; the approved product is synthetic human secretin (ChiRhoStim). |
| Who makes it? | ChiRhoClin, Inc. (Burtonsville, MD); ChiRhoStim received initial US FDA approval in 2004. |
| Approved use | Diagnostic only: pancreatic exocrine function testing, gastrinoma testing, and duct identification during ERCP. |
| Receptor/target | The secretin receptor (SCTR), a class B G-protein-coupled receptor on pancreatic duct cells. |
| Route | Intravenous injection by a clinician, given over about 1 minute. |
| Evidence type | FDA label, pharmacology studies, and diagnostic-test literature; not therapeutic approval. |
How Secretin Works
Secretin is released from S cells in the duodenum when acidic chyme arrives from the stomach. It travels to the pancreas and binds the secretin receptor, a class B (secretin-family) G-protein-coupled receptor expressed on pancreatic duct cells. Receptor activation raises intracellular cyclic AMP, which, per the ChiRhoStim label, opens cystic fibrosis transmembrane conductance regulator (CFTR) channels and drives secretion of a bicarbonate-rich, watery pancreatic fluid.
The physiological purpose is to neutralize stomach acid in the duodenum and create the alkaline environment that pancreatic digestive enzymes need to work. That single, well-characterized action is what the diagnostic test exploits: if you inject secretin and the pancreas does not respond with the expected output, that tells you something about exocrine function.
Secretin also has a secondary, somewhat paradoxical effect on gastrin. In healthy people, secretin tends to suppress gastrin release. In gastrinoma (Zollinger-Ellison syndrome), the tumor cells respond abnormally and gastrin rises after secretin. That reversal is the basis of the secretin stimulation test for gastrinoma.
What The Approved Evidence Actually Supports
The ChiRhoStim label lists three diagnostic indications, and it is precise about each one.
| Indication | What the test does | Key threshold or detail |
|---|---|---|
| Pancreatic exocrine dysfunction | Stimulates pancreatic secretions, including bicarbonate, for collection and measurement. | Reference dose on the label is 0.2 mcg/kg IV over 1 minute. |
| Gastrinoma diagnosis | Stimulates gastrin secretion; gastrinoma cells respond paradoxically. | A rise in serum gastrin of more than 110 pg/mL over baseline strongly suggests gastrinoma. |
| ERCP duct identification | Stimulates secretions to help locate the ampulla of Vater and accessory papilla. | Reference dose on the label is 0.2 mcg/kg IV over 1 minute. |
These dose figures are taken directly from the FDA-approved label and describe how a clinician performs a supervised diagnostic procedure. They are not recommendations, and there is no take-home or repeated dosing schedule for secretin. The gastrinoma dose listed on the label is 0.4 mcg/kg IV over 1 minute. ChiRhoStim is supplied as a lyophilized powder in 16 mcg and 40 mcg single-dose vials that are reconstituted with saline before injection.
For gastrinoma in particular, secretin testing sits alongside other tools. Somatostatin analogs such as octreotide are used in the management of some gastroenteropancreatic neuroendocrine tumors, which is why these compounds often appear in the same clinical conversations even though their purposes differ entirely.
The Failed Therapeutic Story: Autism
No honest secretin overview is complete without the autism episode, because it is a textbook example of anecdote outrunning evidence. In the late 1990s, case reports suggested that a child with autism improved after receiving secretin during an endoscopy. Enthusiasm spread quickly.
The controlled trials did not support it. A 1999 New England Journal of Medicine study by Sandler and colleagues randomized children to a single intravenous dose of synthetic human secretin or placebo and found no benefit on language, behavior, or autism symptom severity. A later Cochrane systematic review pooled 16 randomized controlled trials covering more than 900 children and concluded that there is no evidence that secretin improves autism spectrum disorder.
The lesson is directly relevant to peptide claims today. A real, FDA-approved diagnostic hormone was tested rigorously for a hoped-for therapeutic use and failed. Secretin is genuinely useful, but only for what the controlled evidence supports. Anyone marketing it as an autism, gut-healing, or neurological "treatment" is ignoring one of the better-studied negative results in modern peptide medicine.
Half-Life And Pharmacokinetics
Half-life is a good example of why source labeling matters. Classic radioimmunoassay studies of native secretin in humans found a very short plasma half-life of roughly 4 minutes after intravenous injection. The ChiRhoStim prescribing information, however, reports an elimination half-life of about 45 minutes for the synthetic human secretin product, with plasma concentrations returning toward baseline within roughly 90 to 120 minutes, a clearance near 580 mL/min, and a small volume of distribution of about 2.7 liters.
Both numbers can be cited correctly as long as you say which one you mean: the short value describes rapid clearance of the native hormone in early radioimmunoassay work, while the 45-minute figure is the label's pharmacokinetic value for the approved formulation. This is exactly the kind of nuance covered in the peptide half-life guide. Either way, secretin is cleared quickly enough that the diagnostic test is a short, supervised procedure rather than a sustained exposure.
Safety Considerations
Secretin's safety profile is relatively narrow because it is a single, clinician-administered diagnostic dose rather than chronic therapy. The ChiRhoStim label lists no contraindications, but it does describe several practical cautions, most of which are about getting an accurate test rather than acute danger.
| Safety or test-validity issue | Why it matters |
|---|---|
| Common adverse reactions | Reported reactions include nausea, vomiting, flushing, and upset stomach. |
| Anticholinergic drugs | Can blunt the response and cause a false hyporesponse; the label advises stopping them at least 5 half-lives before testing. |
| H2-blockers and PPIs | Acid-suppressing drugs can cause hyperresponse and a falsely positive gastrinoma result; H2-antagonists are stopped at least 2 days prior. |
| Liver disease | Hepatic disease may mask underlying pancreatic pathology on testing. |
| Hypersensitivity | As with any injected peptide, allergic-type reactions are possible and require clinical readiness. |
Because secretin is given intravenously in a monitored setting, the people administering it are equipped to manage reactions. That supervised context is part of why secretin is not, and should not be, a consumer peptide.
How To Evaluate A Secretin Claim
If you encounter secretin being marketed beyond its label, run through a short checklist.
First, is the claim diagnostic or therapeutic? The only approved uses are diagnostic. Any "treatment" claim is outside the evidence.
Second, does it mention autism, gut healing, or weight loss as established benefits? Those are red flags. The autism program failed in controlled trials, and the obesity-related work remains exploratory physiology, not approved therapy.
Third, is it sold for self-injection? Approved secretin is an intravenous, clinician-administered agent. A vial marketed for home dosing is not the regulated product behaving as intended.
Fourth, does the source distinguish native secretin pharmacology from the ChiRhoStim label? Mixing the 4-minute and 45-minute half-lives without context, or quoting diagnostic doses as if they were a protocol, signals low-quality sourcing.
Other gut peptides such as teduglutide for short bowel syndrome and linaclotide for constipation-related conditions show what a genuine therapeutic gut-peptide label looks like, with defined indications, dosing, and monitoring. Secretin simply does not have one.
Bottom Line
Secretin is a real, well-characterized peptide hormone and an FDA-approved diagnostic medicine. As ChiRhoStim, it is used intravenously by clinicians to stimulate pancreatic bicarbonate secretion for exocrine function testing, to provoke a paradoxical gastrin rise in gastrinoma testing, and to aid duct identification during ERCP. Its mechanism through the secretin receptor and CFTR is clear, and its diagnostic role is well established.
What secretin is not is equally important. It is not a therapeutic peptide, not an autism treatment, and not a self-administered wellness compound. Its most famous attempt at a therapeutic indication failed convincingly in randomized trials. Treat secretin as what the evidence supports: a precise diagnostic tool used in supervised care, with reference doses that describe a procedure rather than a regimen.
References
DailyMed. ChiRhoStim (human secretin) prescribing information.
US FDA. ChiRhoStim (human secretin) approved label, NDA 021256.
US FDA. ChiRhoStim Human Secretin for Injection 40 mcg/vial box label.
Pancreapedia. Secretin receptor.
Pancreapedia. Secretin.
Kolts BE, McGuigan JE. Radioimmunoassay measurement of secretin half-life in man.
Sandler AD, et al. Lack of Benefit of a Single Dose of Synthetic Human Secretin in the Treatment of Autism and Pervasive Developmental Disorder. N Engl J Med. 1999.
Williams K, et al. Intravenous secretin for autism spectrum disorders (Cochrane systematic review).
Volta U, et al. Pleiotropic Effects of Secretin: A Potential Drug Candidate in the Treatment of Obesity? Front Endocrinol. 2021.